Key Takeaways
- FDA's budget authority for fiscal year 2026 will continue to allow for user fees, according to a preliminary budget plan developed by the White House...
The US Food and Drug Administration’s taxpayer funding would decline in fiscal year 2026 compared to 2025 but not enough to trigger suspension of user fees under a preliminary internal...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?